Onco Actu du 20 mars 2020

	1. BIOLOGIE
A Protein That Helps Trap Bacteria May Contribute to Metastasis in a Mouse Model of Breast Cancer [AACR] To understand PAD4 expression levels in breast cancer cells, Wang and colleagues performed a meta-analysis of gene expression profiles from The Cancer Genome Atlas and the Oncomine database.
	1.4 BIOLOGIE - TECHNOS, MODÈLES
New technology helps in hunt for new cancer drug combinations [Walter and Eliza Hall Institute] A joint Walter and Eliza Hall Institute and Stanford University team used a technique called mass cytometry (also called CyTOF) to simultaneously analyse the levels of more than 20 different proteins in millions of individual blood cancer cells.
	2.5 ETIOLOGIE - GÉNOME
NCI study provides genetic insights into osteosarcoma in children [NCI] The researchers found that more people with osteosarcoma carry harmful, or likely harmful, variants in known cancer-susceptibility genes than people without osteosarcoma.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer Treatments [NCI] For the trial, called WINTHER, clinicians matched patients to treatment based on the DNA alterations or RNA levels in the patients’ tumors. The RNA-based approach was only used for patients who didn’t have any tumor DNA alterations that could be matched to a treatment.
	4.10 DÉP., DIAG. & PRONO. - POUMON
AI may help predict responses to non-small cell lung cancer systemic therapies [EurekAlert!] Using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC), researchers utilized artificial intelligence (AI) to train algorithms to predict tumor sensitivity to three systemic cancer therapies.
	4.12 BIOPSIES LIQUIDES
Imaging Could Help ID Brain Cancer Patients Eligible for Plasma Testing [Genome Web] According to Nabavizadeh, because tissue analysis is so dangerous and difficult in brain tumors, liquid biopsy is still in its infancy compared to what has been done for solid tumors elsewhere in the body. As a result these hoped-for clinical implications may be, and how to realize them still remains very unclear.
	5. TRAITEMENTS
Younger men with prostate cancer benefit from more aggressive treatment [UPI] Researchers noted that those who received so-called "non-definitive therapy" -- either systemic therapy or no initial therapy -- were more than twice as likely to die from the disease than those who underwent more aggressive treatment, including surgical removal of the prostate or radiotherapy.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
New Drug Combination Passes Safety Test in Pancreatic Cancer [Mary Ann Liebert] The purpose of this open label phase 1a study was to determine the maximum tolerated dose, safety, and tolerability of LY2510924, a CXCR4 peptide antagonist with proven, significant antitumor activity in preclinical studies, given in combination with the PD-1 inhibitor durvalumab.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies [Xconomy] “Solid tumors are very different from blood cancers in that they build a castle, a defense system,” Eureka CEO Cheng Liu said. “For engineered T cell therapy you need technologies that promote T cell infiltration to solid tumors.”
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers [MD Anderson Cancer Center] The open-label, Phase II study followed 127 patients who had advanced rare cancers: squamous cell carcinoma of the skin (cSCC), carcinoma of unknown primary (CUP), adrenocortical carcinoma (ACC), and paraganglioma-pheochromocytoma.
	5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
Soligenix's stock climbs as phase 3 lymphoma trial hits goal [Fierce Biotech] New Jersey-based Soligenix designed the trial to test SGX301, a synthetic form of hypericin. Soligenix moved the drug into phase 3 in the belief it is taken up by malignant T cells and, when activated by fluorescent light, inhibits their growth.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
Lynparza granted orphan drug designation in Japan for BRCA-mutated metastatic pancreatic cancer [AstraZeneca] Designation based on the Phase III POLO trial that showed Lynparza (olaparib) nearly doubled the time patients lived without disease progression vs. placebo.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Moleculin advances plan to strip and starve COVID-19 [Fierce Biotech] Houston-based Moleculin originally identified WP1122 as a potential treatment for pancreatic cancer and glioblastoma multiforme.
Coronavirus lockdown: What I learnt when I shut my cancer lab in 48 hours [Nature] Doing science during the quarantine in northern Italy has shown me that creativity needs connection. By Alberto Bardelli.